Do you want to read an article? Please log in or register.
Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
CFTR modulator theratyping: Current status, gaps and future directions
J Cyst Fibros.
Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL
doi: 10.1016/j.jcf.2018.05.004.
RECOMMENDED
Lung Cancer
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Noordhof AL, Damhuis RAM, Hendriks LEL, de Langen AJ, Timens W, Venmans BJW, van Geffen WH
doi: 10.1016/j.lungcan.2021.04.001
Pulmonary Fibrosis
Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis
Am J Respir Crit Care Med.
Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B
doi: 10.1164/
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/
CoughPulmonary Fibrosis
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Lancet Respir Med.
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.
doi: 10.1016/
RECOMMENDED
Lung Cancer
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
doi: 10.1016/S1470-2045(20)30093-0.
Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis
BMC Pulm Med.
Gomez CCS, Marson FAL, Servidoni MF, Ribeiro AF, Ribeiro MÂGO, Gama VAL, Costa ET, Ribeiro JD, Vieira Junior FU
doi: 10.1186/s12890-018-0696-3.
RECOMMENDED
Lung Cancer
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 3
Recommended by
Alexander Meisel, Faculty Member
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, RELAY Study Investigators.
doi: 10.1016/S1470-2045(19)30634-5.
COPD
Feasibility of deriving a novel imaging biomarker based on patient-specific lung elasticity for characterizing the degree of COPD in lung SBRT patients
Br J Radiol. 2
Hasse K, Neylon J, Min Y, O'Connell D, Lee P, Low DA, Santhanam AP
doi: 10.1259/bjr.20180296.